Alopecia Secondary to Severe Discoid Lupus Responding to Anifrolumab

A 21-year-old woman with severe discoid lupus erythematosus (DLE) and associated alopecia showed significant improvement after being treated with anifrolumab (ANI), a monoclonal antibody targeting type I interferon receptor subunit 1. Despite previous treatments with various immunosuppressants and antimalarials, the patient had minimal response and difficulty adhering to the regimen. After starting ANI, she exhibited notable improvement in cutaneous lesions and impressive hair regrowth within 7 months. ANI demonstrated a favorable side effect profile and good tolerability, suggesting it as a viable therapeutic option for refractory or severe DLE. Future studies could explore ANI monotherapy to enhance medication adherence and reduce adverse effects associated with traditional therapies.